DrugPatentWatch Database Preview

UPTRAVI Drug Profile

« Back to Dashboard

Which patents cover Uptravi, and what generic alternatives are available?

Uptravi is a drug marketed by Actelion Pharms Ltd and is included in one NDA. There are four patents protecting this drug.

The generic ingredient in UPTRAVI is selexipag. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the selexipag profile page.

Summary for UPTRAVI

US Patents:	4
Applicants:	1
NDAs:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	38
Clinical Trials:	2
Patent Applications:	27
Drug Prices:	Drug price information for UPTRAVI
DailyMed Link:	UPTRAVI at DailyMed

Generic Entry Opportunity Date for UPTRAVI

NDA:

207947

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for UPTRAVI

Drug Class	Prostacyclin Receptor Agonist
Mechanism of Action	Prostacyclin Receptor Agonists

Synonyms for UPTRAVI

144383-EP2289518A1

144383-EP2292231A1

2-?[4-?[(5,?6-?DIPHENYLPYRAZINYL)(1-?METHYLETHYL)AMINO]BUTOXY]-?N-?(METHYLSULFONYL)-?ACETAMIDE

2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide

2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide

2-(4-((5,6-Diphenylpyrazinyl)(1-methylethyl)amino)butoxy)-N-(methylsulfonyl)-acetamide

2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-N-(methylsulfonyl)acetamide

2-[4-[[5,6-di(phenyl)pyrazin-2-yl]-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide

2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide

2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-methanesulfonylacetamide

2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide

3938AH

475086-01-2

5EXC0E384L

ACT 293987

ACT-293987

ACT293987

AK298890

AKOS024457572

B7378

CHEBI:90844

CHEMBL238804

CS-3774

CTK8F0123

D09994

D0N2SR

DB11362

GTPL7552

HE092855

HY-14870

IN2104

KB-79567

KS-00000L89

MFCD10567093

MolPort-009-019-323

NS 304

NS-304

NS-304(Selexipag)

QXWZQTURMXZVHJ-UHFFFAOYSA-N

RT-014761

SCHEMBL674122

Selexipag

Selexipag (JAN/USAN/INN)

Selexipag [USAN:INN]

UNII-5EXC0E384L

Uptravi (TN)

ZINC3990451

US Patents and Regulatory Information for UPTRAVI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actelion Pharms Ltd	UPTRAVI	selexipag	TABLET;ORAL	207947-007	Dec 21, 2015		RX	Yes	No
Actelion Pharms Ltd	UPTRAVI	selexipag	TABLET;ORAL	207947-006	Dec 21, 2015		RX	Yes	No			Y	Y
Actelion Pharms Ltd	UPTRAVI	selexipag	TABLET;ORAL	207947-008	Dec 21, 2015		RX	Yes	Yes
Actelion Pharms Ltd	UPTRAVI	selexipag	TABLET;ORAL	207947-005	Dec 21, 2015		RX	Yes	No			Y	Y

International Patents for UPTRAVI

Country	Document Number	Estimated Expiration
Mexico	346318
Argentina	077242
China	1516690
China	102459198

Supplementary Protection Certificates for UPTRAVI

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
90044-1	Sweden		PRODUCT NAME: SELEXIPAG OR SALT THEROF; REG. NO/DATE: EU/1/15/1083 20160519
0836	Netherlands		PRODUCT NAME: SELEXIPAG OF EEN ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/15/1083 20160519
/2016	Austria		PRODUCT NAME: SELEXIPAG ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083 (MITTEILUNG) 20160519
2016 00048	Denmark		PRODUCT NAME: SELEXIPAG ELLER ET SALT DERAF; REG. NO/DATE: EU/1/15/1083 20160519